VivoSeq
Other

Hyperandrogenism

6

Pipeline Programs↗

3

Active Trials↗

4

Companies Involved↗

Hyperandrogenism is an early-stage landscape with 6 programs across 4 companies. The most active players are Pfizer, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, AbbVie.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Phase 1A

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

1 program

Phase 1AbbVie logo

AbbVie

1 program

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

5

clinical trials

Recruiting3 · 60%
Completed1 · 20%
Unknown status1 · 20%

Clinical Trials

Trial Activity

Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
Recruiting·UUniversity of Virginia·Phase 1·NCT00929006·36 enrolled
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Recruiting·UUniversity of Virginia·Phase 1·NCT03905603·144 enrolled
Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism
Completed·NNational Center for Research Resources (NCRR)·Phase 2·NCT00004763·45 enrolled
Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism?
Recruiting·UUniversity of Virginia·Phase 1·NCT04723862·32 enrolled
Comparison of Metformin and Pioglitazone in Regulating Menstrual Irregularities and Hyperandrogenism
Unknown status·—·Phase 1/2·NCT03757923·110 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)